The global neurological rare disease biologics market is driven by advances in monoclonal antibodies, gene therapies, and personalized medicine. Biologics help improve outcomes in conditions with limited treatment options. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neurological Rare Disease Biologics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neurological Rare Disease Biologics Market, by Disease Type
8.1.1. Spinal Muscular Atrophy (SMA)
8.1.1.1. Market Revenue and Forecast
8.1.2. Hereditary Neuropathies (e.g., Charcot-Marie-Tooth)
8.1.2.1. Market Revenue and Forecast
8.1.3. Lysosomal Storage Disorders with Neurological Involvement
8.1.3.1. Market Revenue and Forecast
8.1.4. Rett Syndrome & Rett-like Disorders
8.1.4.1. Market Revenue and Forecast
8.1.5. Hereditary Ataxias (e.g., Friedreich’s, Spinocerebellar)
8.1.5.1. Market Revenue and Forecast
8.1.6. Rare ALS & Motor Neuron Diseases
8.1.6.1. Market Revenue and Forecast
8.1.7. Huntington’s Disease Subpopulations
8.1.7.1. Market Revenue and Forecast
8.1.8. Ultra-Rare Pediatric Neurodegenerative Disorders
8.1.8.1. Market Revenue and Forecast
9.1. Neurological Rare Disease Biologics Market, by Therapy Type
9.1.1. Gene Therapies (AAV, Lentiviral, Gene Editing)
9.1.1.1. Market Revenue and Forecast
9.1.2. Oligonucleotide Therapeutics (ASOs, siRNA, Splice Modulators)
9.1.2.1. Market Revenue and Forecast
9.1.3. Monoclonal Antibodies & Biologic Proteins
9.1.3.1. Market Revenue and Forecast
9.1.4. Enzyme Replacement Therapies (ERT)
9.1.4.1. Market Revenue and Forecast
9.1.5. Cell Therapies (Neural Stem Cells, MSCs, CAR-T Variants)
9.1.5.1. Market Revenue and Forecast
9.1.6. Therapeutic Proteins & Peptides
9.1.6.1. Market Revenue and Forecast
10.1. Neurological Rare Disease Biologics Market, by Drug Class / Mechanism
10.1.1. Exon-Skipping ASOs
10.1.1.1. Market Revenue and Forecast
10.1.2. RNAi Therapeutics (siRNA)
10.1.2.1. Market Revenue and Forecast
10.1.3. AAV-Based Gene Replacement
10.1.3.1. Market Revenue and Forecast
10.1.4. CRISPR/Base Editing Modalities
10.1.4.1. Market Revenue and Forecast
10.1.5. Recombinant Enzymes & Fusion Proteins
10.1.5.1. Market Revenue and Forecast
10.1.6. Neurotrophic Factor Agonists
10.1.6.1. Market Revenue and Forecast
10.1.7. Anti-Neuroinflammatory mAbs
10.1.7.1. Market Revenue and Forecast
11.1. Neurological Rare Disease Biologics Market, by Product Type
11.1.1. Originator Branded Biologics & Gene Therapies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biosimilars & Follow-On Biologics
11.1.2.1. Market Revenue and Forecast
11.1.3. Platform Therapeutics (Licensed Programs)
11.1.3.1. Market Revenue and Forecast
11.1.4. Cell Therapy Products
11.1.4.1. Market Revenue and Forecast
12.1. Neurological Rare Disease Biologics Market, by Distribution Channel
12.1.1. Hospital Procurement
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Pharmacies
12.1.2.1. Market Revenue and Forecast
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type
13.1.2. Market Revenue and Forecast, by Therapy Type
13.1.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.4. Market Revenue and Forecast, by Product Type
13.1.5. Market Revenue and Forecast, by Distribution Channel
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type
13.1.6.2. Market Revenue and Forecast, by Therapy Type
13.1.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.6.4. Market Revenue and Forecast, by Product Type
13.1.6.5. Market Revenue and Forecast, by Distribution Channel
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease Type
13.1.7.2. Market Revenue and Forecast, by Therapy Type
13.1.7.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.7.4. Market Revenue and Forecast, by Product Type
13.1.7.5. Market Revenue and Forecast, by Distribution Channel
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type
13.2.2. Market Revenue and Forecast, by Therapy Type
13.2.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.4. Market Revenue and Forecast, by Product Type
13.2.5. Market Revenue and Forecast, by Distribution Channel
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type
13.2.6.2. Market Revenue and Forecast, by Therapy Type
13.2.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.7. Market Revenue and Forecast, by Product Type
13.2.8. Market Revenue and Forecast, by Distribution Channel
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type
13.2.9.2. Market Revenue and Forecast, by Therapy Type
13.2.9.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.10. Market Revenue and Forecast, by Product Type
13.2.11. Market Revenue and Forecast, by Distribution Channel
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type
13.2.12.2. Market Revenue and Forecast, by Therapy Type
13.2.12.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.12.4. Market Revenue and Forecast, by Product Type
13.2.13. Market Revenue and Forecast, by Distribution Channel
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type
13.2.14.2. Market Revenue and Forecast, by Therapy Type
13.2.14.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.14.4. Market Revenue and Forecast, by Product Type
13.2.15. Market Revenue and Forecast, by Distribution Channel
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type
13.3.2. Market Revenue and Forecast, by Therapy Type
13.3.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.4. Market Revenue and Forecast, by Product Type
13.3.5. Market Revenue and Forecast, by Distribution Channel
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type
13.3.6.2. Market Revenue and Forecast, by Therapy Type
13.3.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.6.4. Market Revenue and Forecast, by Product Type
13.3.7. Market Revenue and Forecast, by Distribution Channel
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type
13.3.8.2. Market Revenue and Forecast, by Therapy Type
13.3.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.8.4. Market Revenue and Forecast, by Product Type
13.3.9. Market Revenue and Forecast, by Distribution Channel
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type
13.3.10.2. Market Revenue and Forecast, by Therapy Type
13.3.10.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.10.4. Market Revenue and Forecast, by Product Type
13.3.10.5. Market Revenue and Forecast, by Distribution Channel
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type
13.3.11.2. Market Revenue and Forecast, by Therapy Type
13.3.11.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.11.4. Market Revenue and Forecast, by Product Type
13.3.11.5. Market Revenue and Forecast, by Distribution Channel
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type
13.4.2. Market Revenue and Forecast, by Therapy Type
13.4.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.4. Market Revenue and Forecast, by Product Type
13.4.5. Market Revenue and Forecast, by Distribution Channel
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type
13.4.6.2. Market Revenue and Forecast, by Therapy Type
13.4.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.6.4. Market Revenue and Forecast, by Product Type
13.4.7. Market Revenue and Forecast, by Distribution Channel
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type
13.4.8.2. Market Revenue and Forecast, by Therapy Type
13.4.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.8.4. Market Revenue and Forecast, by Product Type
13.4.9. Market Revenue and Forecast, by Distribution Channel
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type
13.4.10.2. Market Revenue and Forecast, by Therapy Type
13.4.10.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.10.4. Market Revenue and Forecast, by Product Type
13.4.10.5. Market Revenue and Forecast, by Distribution Channel
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type
13.4.11.2. Market Revenue and Forecast, by Therapy Type
13.4.11.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.11.4. Market Revenue and Forecast, by Product Type
13.4.11.5. Market Revenue and Forecast, by Distribution Channel
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type
13.5.2. Market Revenue and Forecast, by Therapy Type
13.5.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.4. Market Revenue and Forecast, by Product Type
13.5.5. Market Revenue and Forecast, by Distribution Channel
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type
13.5.6.2. Market Revenue and Forecast, by Therapy Type
13.5.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.6.4. Market Revenue and Forecast, by Product Type
13.5.7. Market Revenue and Forecast, by Distribution Channel
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type
13.5.8.2. Market Revenue and Forecast, by Therapy Type
13.5.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.8.4. Market Revenue and Forecast, by Product Type
13.5.8.5. Market Revenue and Forecast, by Distribution Channel
14.1. Alexion (AstraZeneca)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Biogen
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Bluebird bio
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Catalent
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Eli Lilly
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Ionis Pharmaceuticals
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Novartis
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Pfizer
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Regenxbio
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description